Kexing Biopharm, a Chinese biopharmaceutical company headquartered in Shangdong Province, developed a COVID-19 vaccine, CoronaVac. Brazil has been conducting stage 3 testing of this vaccine. It recently reported that the vaccine’s effective rate was 50.38 percent. The two vaccines of the U.S. Company Pfizer had a 95 percent efficacy rate and Moderna had a 94.1 percent rate.
China’s vaccine passed the 50 percent mark that World Health Organization set. However, its low efficacy rate impacted Beijing’s bid to use the vaccine to boost its international influence.
Over ten countries have pre-ordered 380 million of China’s CoronaVac vaccine.
Excerpt in Chinese:
Source: Radio France International, January 14, 2021